Search Result

Results for "

SARS-CoV-2 variants

" in MedChemExpress (MCE) Product Catalog:

By Targets:	SARS-CoV (66) Angiotensin-converting Enzyme (ACE) (1) Cytochrome P450 (1) Dengue Virus (1) Deubiquitinase (3) DNA/RNA Synthesis (2) Enterovirus (1) Filovirus (1) Glycosidase (1) HCV (4) HCV Protease (4) Histone Demethylase (2) HIV (1) nAChR (1) Reference Standards (1) RSV (1) Ser/Thr Protease (1) STING (1) Virus Protease (15)
By Research Areas:	Cancer (3) Infection (63) Inflammation/Immunology (4) Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

GMP Molecules

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15298

Grazoprevir Maximum Cited Publications 29 Publications Verification MK-5172	HCV Protease HCV SARS-CoV	Infection
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-138794

XL177A 5 Publications Verification	Deubiquitinase Histone Demethylase SARS-CoV	Cancer
XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including *SARS-CoV-2* variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

HY-N2183

Baimaside 3 Publications Verification Quercetin 3-O-sophoroside	SARS-CoV	Infection Neurological Disease
Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to *SARS-CoV-2*-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of *SARS-CoV-2* and its variants, making it suitable for research related to Alzheimer's disease and COVID-19 .

HY-172437

Secutrelvir S-892216	Virus Protease SARS-CoV	Infection
Secutrelvir is an oral SARS-CoV-2 3C-like protease (3CLpro) inhibitor and antiviral agent, with IC₅₀ values of 0.655 nM and 0.697 nM against SARS-CoV-2 3CLpro, respectively. Secutrelvir forms a reversible covalent bond with the catalytic cysteine C145 of SARS-CoV-2 3CLpro, thereby inhibiting viral replication. Secutrelvir exhibits activity against multiple SARS-CoV-2 variants and can be used in research related to coronavirus disease 2019 (COVID-19) .

HY-133894

Bofutrelvir FB2001	SARS-CoV	Infection
Bofutrelvir (FB2001) is a SARS-CoV-2 main protease M ^pro inhibitor with an IC₅₀ value of 53 nM and an EC₅₀ value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC₅₀ values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077) .

HY-152955

STING agonist-22 1 Publications Verification	STING	Infection Inflammation/Immunology
STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research .

HY-145994

Obeldesivir 1 Publications Verification ATV006	SARS-CoV	Infection
Obeldesivir (ATV006) is a potent, orally active antiviral agent and ester proagents of GS-441524. Obeldesivir inhibits the replication of SARS-CoV-2 and its variants. Obeldesivir can be used for SARS-CoV-2 research .

HY-172760

CIM-834	SARS-CoV	Infection
CIM-834 is an orally effective inhibitor of SARS-CoV-2 membrane protein. CIM-834 can prevent the assembly of infectious virus particles without inhibiting the synthesis of viral RNA. CIM-834 can reduce the viral titer in the lungs of SCID mice infected nasally with SARS-CoV-2, block the spread of SARS-CoV-2 among Syrian hamsters, and inhibit the replication of SARS-CoV-2 (including variants) and SARS-CoV. CIM-834 can be used in related research on COVID-19 .

HY-P99423

Adintrevimab 2 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

HY-15298A

Grazoprevir potassium salt Maximum Cited Publications 29 Publications Verification MK-5172 potassium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir potassium salt inhibits SARS-CoV-2 3CL ^pro activity .

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-153228

Pomotrelvir 1 Publications Verification PBI-0451	SARS-CoV	Infection
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (M ^pro), with an IC₅₀ of 24 nM for wild-type SARS-CoV-2 M ^pro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants .

HY-P99103

Bebtelovimab LY-3853113; LY-CoV1404	SARS-CoV	Infection
Bebtelovimab a human IgG1-λ2 antibody targeting to *SARS-CoV-2, especially COVID-19 ((the IC₅₀* value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P99341

Casirivimab 1 Publications Verification REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody that targets the *SARS-CoV-2* virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .

HY-149535

Iscartrelvir WU-04	SARS-CoV	Infection
Iscartrelvir (WU-04) is a non-covalent inhibitor of *SARS-CoV-2, targeting the 3CLpro protein. Iscartrelvir has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2* variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .

HY-15298B

Grazoprevir hydrate Maximum Cited Publications 29 Publications Verification MK-5172 hydrate	HCV HCV Protease SARS-CoV	Infection
Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir hydrate inhibits SARS-CoV-2 3CL ^pro activity .

HY-139582

Simpinicline OC-02	nAChR SARS-CoV	Infection
Simpinicline (OC-02), a highly selective nicotinic acetylcholine receptor (nAChR) agonist, shows potent antiviral activity against the SARS-CoV-2 variants in cell culture with an IC₅₀ of 0.04 µM .

HY-161356

BPR3P0128	DNA/RNA Synthesis SARS-CoV	Infection
BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various *SARS-CoV-2* variants. The EC₅₀ for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .

HY-176264

DNDI-6510	SARS-CoV Virus Protease Cytochrome P450	Infection
DNDI-6510 (Compound (S)-x38) is a non-covalent SARS-CoV-2 MPro inhibitor with a IC₅₀ of 0.04 μM. DNDI-6510 has a potent antiviral activity across SARS-CoV-2 and its variants as well as a weak efficacy to SARS-CoV-1. DNDI-6510 significantly improves drug exposure in metabolically humanized mice model (8HUM) .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-161844

Virapinib	SARS-CoV Dengue Virus	Infection
Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against *SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus* infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection .

HY-162484

GZNL-P36	SARS-CoV Virus Protease	Infection
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL ^pro), with an IC₅₀ of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC₅₀ range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration C_max of 549 ng/mL, a half-life T_1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .

HY-138794A

(Rac)-XL177A	Deubiquitinase	Cancer
(Rac)-XL177A is the racemic isomer of XL177A (HY-138794). XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including *SARS-CoV-2* variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

HY-168916

Jun13296	SARS-CoV Virus Protease
Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC₅₀ = 0.13 µM, K_i = 8.8 nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model .

HY-175344

TMP1	SARS-CoV Virus Protease Ser/Thr Protease	Infection Inflammation/Immunology
TMP1 is an orally active bispecific inhibitor of M pro (IC₅₀ = 312.5 nM)/TMPRSS2 (IC₅₀ = 1.28 μM, K_D = 10.10 μM). TMP1 exhibits broad protection against different *SARS-CoV-2* variants in vitro. TMP1 cross-protects against highly pathogenic coronaviruses (SARS-CoV-1, *SARS-CoV-2, and MERS-CoV) in vivo and effectively blocks the transmission of SARS-CoV-2. TMP1 can inhibit infection by SARS-CoV-2* escape mutants that are resistant to Nivolumab (HY-P9903). TMP1 can be used in coronavirus research .

HY-175029

ALG-097558	SARS-CoV Virus Protease	Infection
ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various *SARS-CoV-2* variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC₅₀s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].

HY-178435

SARS-CoV-2 Mpro-IN-48	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-48 is a potent *SARS-CoV-2* main protease inhibitor with an IC₅₀ of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19 .

HY-173148

TKB272	SARS-CoV	Infection
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of *SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2* strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC₅₀ of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC₅₀ as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC₅₀ of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .

HY-109072

Riamilovir	DNA/RNA Synthesis SARS-CoV	Infection
Riamilovir is an antiviral drug whose activity is primarily directed against RNA viruses. Riamilovir acts directly on the virus's RNA-dependent RNA polymerase, thereby preventing the virus from replicating. This mechanism allows Riamilovir to effectively reduce the amount of virus, accelerate the relief of symptoms, and help reduce the severity of the disease. Riamilovir can be used in the study of acute respiratory viral infections caused by new variants of *SARS-CoV-2* .

HY-151988

SARS-CoV-2-IN-36	SARS-CoV	Infection
SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC₅₀ of 2.37 μM and a K_d of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells .

HY-15298C

Grazoprevir sodium salt MK-5172 sodium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir sodium salt inhibits SARS-CoV-2 3CL ^pro activity .

HY-175712

SARS-CoV-2 Mpro-IN-47	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-47 is an orally active SARS-CoV-2 Mpro reversible covalent Inhibitor. SARS-CoV-2 Mpro-IN-47 shows potent antiviral activity against several clinical variants of SARS-CoV-2. SARS-CoV-2 Mpro-IN-47 can be used for the research of infection, such as SARS-CoV-2 .

HY-168600

SARS-CoV-2 Mpro-IN-32	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 M ^Pro with an IC₅₀ value of 230 nM. SARS-CoV-2 Mpro-IN-32 can also inhibit the replication of multiple *SARS-CoV-2* variants in vitro .

HY-174385

SARS-CoV-2-IN-114	SARS-CoV	Infection
SARS-CoV-2-IN-114 (Compound 36) is an antiviral agent. SARS-CoV-2-IN-114 exhibits significant antiviral activity against both the *SARS-CoV-2* original strain and the Delta variant. SARS-CoV-2-IN-114 has an EC₅₀ of 0.29 μM for inhibiting CPE of the *SARS-CoV-2* original strain, and that for the Delta variant is 5.77 μM. SARS-CoV-2-IN-114 has low cytotoxicity and can be used in coronavirus research .

HY-169224

SARS-CoV-2-IN-100	SARS-CoV	Infection
SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of *SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2* variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a *SARS-CoV-2* inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-P10976

Spike Glycoprotein (1147-1162)	SARS-CoV	Infection
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of *SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2* variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .

HY-178772

SARS-CoV-2 Mpro-IN-50	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-50 (Compound 30) is a noncovalent SARS-CoV-2 Mpro inhibitor with an IC₅₀ of 14  nM. SARS-CoV-2 Mpro-IN-50 is also a pan-CoV Mpro inhibitor with IC₅₀s of 20-190 nM for SARS-CoV-1 Mpro, 229E Mpro, HKU1 Mpro, MERS Mpro, NL63 Mpro and OC43 Mpro. SARS-CoV-2 Mpro-IN-50 has significant antiviral activity against the SARS-CoV-2 omicron variant (EC₅₀: 22  nM). SARS-CoV-2 Mpro-IN-50 can be used for coronavirus infections research .

HY-161777

SARS-CoV-2 Mpro-IN-23	SARS-CoV Virus Protease	Infection
SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC₅₀ of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC₅₀ of 0.02-0.52 μM .

HY-159477

SARS-CoV-2-IN-92	SARS-CoV	Infection Inflammation/Immunology
SARS-CoV-2-IN-92 (compound 11) inhibits *SARS-CoV-2* variants (EC₅₀ = 0.48 μM), as well as SARS-CoV and MERS-CoV. SARS-CoV-2-IN-92 (compound 11) potently and selectively blocks ERα-Glu II .

HY-162550

Jobosic acid	SARS-CoV	Infection
Jobosic acid, a saturated fatty acid, is a selective *SARS-CoV-2* inhibitor. Jobosic acid inhibits Mpro and spike-RBD/ACE-2 interaction with IC₅₀ values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid shows viral entry inhibition for the omicron SARS-CoV-2 variant .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-149368

SARS-CoV-2-IN-51	SARS-CoV	Infection
SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC₅₀s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state .

HY-151265

MMT5-14	SARS-CoV	Infection
MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of *SARS-CoV-2* than Remdesivir (HY-104077). MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC₅₀s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19 .

HY-172214

AB-343	SARS-CoV Virus Protease	Infection
AB-343 is a selective covalent inhibitor of SARS-CoV-2 Mpro, with an IC₅₀ of 8 nM and a K_i of 2.8 nM. AB-343 can effectively inhibit the main proteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-168917

9-Aminominocycline 9-AMN	SARS-CoV Virus Protease	Infection
9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC₅₀ of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC₅₀ of 1.04 µM and 2.35 µM .

HY-155144

CDD-1845	SARS-CoV	Infection
CDD-1845 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a K_i of 3 nM. CDD-1845 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .

HY-155142

CDD-1819	SARS-CoV	Infection
CDD-1819 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a K_i of 5 nM. CDD-1819 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .

HY-155143

CDD-1733	SARS-CoV	Infection
CDD-1733 is a non-covalent and non-peptide potent SARS-CoV-2 Mpro inhibitor with a K_i of 12 nM. CDD-1733 also inhibits ΔP168, A173V, and ΔP168/A173V Mpro variants .

Cat. No.	Product Name	Type

HY-138794G

XL177A

Fluorescent Dyes

XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

Cat. No.	Product Name	Type

HY-138794G

XL177A

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P10976

Spike Glycoprotein (1147-1162)	SARS-CoV	Infection
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of *SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2* variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P10855

S1b3inL1	SARS-CoV	Infection
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .

HY-173459

N-0920	SARS-CoV	Infection
N-0920 is a potent TMPRSS2 inhibitor with an IC₅₀ of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC₅₀s values of 300 pM and 90 pM, respectively .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99423

Adintrevimab 2 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

HY-P99344

Bamlanivimab Anti-Human SARS-CoV-2	SARS-CoV	Infection
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .

HY-P99103

Bebtelovimab LY-3853113; LY-CoV1404	SARS-CoV	Infection
Bebtelovimab a human IgG1-λ2 antibody targeting to *SARS-CoV-2, especially COVID-19 ((the IC₅₀* value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P99341

Casirivimab 1 Publications Verification REGN10933	SARS-CoV	Infection
Casirivimab (REGN10933) is a human monoclonal antibody that targets the *SARS-CoV-2* virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P991763

Anti-SARS-CoV-2 S protein (RBD) Antibody (SARS2-38)	SARS-CoV	Infection
Anti-SARS-CoV-2 S protein (RBD) Antibody (SARS2-38) reacts with many variants of *SARS-CoV-2* that binds a conserved epitope on the RBD (amino acids K444 and G446). Anti-SARS-CoV-2 S protein (RBD) Antibody (SARS2-38) does not cross-react with the SARS-CoV-1 spike protein. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2183

Baimaside 3 Publications Verification Quercetin 3-O-sophoroside	Apocynaceae Flavonols Structural Classification Flavonoids Classification of Application Fields Other Diseases Phenols Polyphenols Plants Apocynum venetum Linn. Disease Research Fields Source Classification	SARS-CoV
Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to *SARS-CoV-2*-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of *SARS-CoV-2* and its variants, making it suitable for research related to Alzheimer's disease and COVID-19 .

HY-N2183R

Baimaside (Standard) Quercetin 3-O-sophoroside (Standard)	Apocynaceae Flavonols Structural Classification Flavonoids Phenols Polyphenols Plants Apocynum venetum Linn. Source Classification	Reference Standards SARS-CoV
Baimaside (Standard) is the analytical standard of Baimaside. This product is intended for research and analytical applications. Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to *SARS-CoV-2*-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of *SARS-CoV-2* and its variants, making it suitable for research related to Alzheimer's disease and COVID-19 .

Targets Recommended: SARS-CoV

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138794G

XL177A	Deubiquitinase SARS-CoV Histone Demethylase	Cancer
XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including *SARS-CoV-2* variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SARS-CoV-2 variants

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

GMP Molecules

Natural
Products